{"id": "article-148244_0", "title": "Nirmatrelvir-Ritonavir -- Continuing Education Activity", "content": "Nirmatrelvir/ritonavir also referred to as ritonavir-boosted nirmatrelvir, is an oral combination medication used to treat coronavirus disease 2019 (COVID-19). It consists of nirmatrelvir, a protease inhibitor targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, and ritonavir, a cytochrome P450 (CYP) 3A inhibitor. Nirmatrelvir/ritonavir was authorized for emergency use on December 22, 2021. It is currently one of the highly-effective oral antiviral medications available to treat COVID-19. This activity reviews the medication\u2019s indications and contraindications. It also reviews the mechanism of action, administration, monitoring, adverse effects, toxicity, and other elements related to treating patients with COVID-19. Information in this activity is pertinent to all members of the interprofessional healthcare team, including physicians, pharmacists, nurses, and other health professionals, who manage the care of patients with COVID-19.", "contents": "Nirmatrelvir-Ritonavir -- Continuing Education Activity. Nirmatrelvir/ritonavir also referred to as ritonavir-boosted nirmatrelvir, is an oral combination medication used to treat coronavirus disease 2019 (COVID-19). It consists of nirmatrelvir, a protease inhibitor targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, and ritonavir, a cytochrome P450 (CYP) 3A inhibitor. Nirmatrelvir/ritonavir was authorized for emergency use on December 22, 2021. It is currently one of the highly-effective oral antiviral medications available to treat COVID-19. This activity reviews the medication\u2019s indications and contraindications. It also reviews the mechanism of action, administration, monitoring, adverse effects, toxicity, and other elements related to treating patients with COVID-19. Information in this activity is pertinent to all members of the interprofessional healthcare team, including physicians, pharmacists, nurses, and other health professionals, who manage the care of patients with COVID-19."}
{"id": "article-148244_1", "title": "Nirmatrelvir-Ritonavir -- Continuing Education Activity", "content": "Objectives: Outline the indications for using nirmatrelvir/ritonavir. Explain the potential adverse effects of nirmatrelvir/ritonavir. Describe the mechanism of action of nirmatrelvir/ritonavir. Summarize the contraindications of using nirmatrelvir/ritonavir to treat patients with COVID-19. Access free multiple choice questions on this topic.", "contents": "Nirmatrelvir-Ritonavir -- Continuing Education Activity. Objectives: Outline the indications for using nirmatrelvir/ritonavir. Explain the potential adverse effects of nirmatrelvir/ritonavir. Describe the mechanism of action of nirmatrelvir/ritonavir. Summarize the contraindications of using nirmatrelvir/ritonavir to treat patients with COVID-19. Access free multiple choice questions on this topic."}
{"id": "article-148244_2", "title": "Nirmatrelvir-Ritonavir -- Indications", "content": "On December 22nd, 2021, the United States (US) Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for nirmatrelvir/ritonavir, allowing its use in the treatment of COVID-19. [1] [2] Specifically, it is used to treat mild-to-moderate COVID-19 in patients who have a SARS-CoV-2-positive test, are at least 12 years of age, weigh at least 40 kilograms (88 pounds), are not hospitalized due to COVID-19, and have a high risk of clinical progression to severe disease which includes hospitalization and death. [3]", "contents": "Nirmatrelvir-Ritonavir -- Indications. On December 22nd, 2021, the United States (US) Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for nirmatrelvir/ritonavir, allowing its use in the treatment of COVID-19. [1] [2] Specifically, it is used to treat mild-to-moderate COVID-19 in patients who have a SARS-CoV-2-positive test, are at least 12 years of age, weigh at least 40 kilograms (88 pounds), are not hospitalized due to COVID-19, and have a high risk of clinical progression to severe disease which includes hospitalization and death. [3]"}
{"id": "article-148244_3", "title": "Nirmatrelvir-Ritonavir -- Indications", "content": "According to Charlson's comorbidity index, underlying comorbidities associated with severe disease outcomes are chronic pulmonary disease(including asthma), diabetes mellitus, older age, male sex, obesity, coronary artery disease, congestive heart failure, dementia, liver disease,\u00a0chronic kidney\u00a0disease, solid tumor with metastasis, and immunosuppression. [4] [5] [6]", "contents": "Nirmatrelvir-Ritonavir -- Indications. According to Charlson's comorbidity index, underlying comorbidities associated with severe disease outcomes are chronic pulmonary disease(including asthma), diabetes mellitus, older age, male sex, obesity, coronary artery disease, congestive heart failure, dementia, liver disease,\u00a0chronic kidney\u00a0disease, solid tumor with metastasis, and immunosuppression. [4] [5] [6]"}
{"id": "article-148244_4", "title": "Nirmatrelvir-Ritonavir -- Indications", "content": "As demonstrated by the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir/ritonavir in these patients within five days of the onset of symptoms reduced the risk of COVID-19-related hospital admission or death by 89%. [7] [8] Studies demonstrate that its\u00a0efficacy is comparable to that of remdesivir and greater than that of molnupiravir. [9] [10] Nirmatrelvir/ritonavir is also efficacious against the Omicron variant and its subvariants. [11] [12]", "contents": "Nirmatrelvir-Ritonavir -- Indications. As demonstrated by the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir/ritonavir in these patients within five days of the onset of symptoms reduced the risk of COVID-19-related hospital admission or death by 89%. [7] [8] Studies demonstrate that its\u00a0efficacy is comparable to that of remdesivir and greater than that of molnupiravir. [9] [10] Nirmatrelvir/ritonavir is also efficacious against the Omicron variant and its subvariants. [11] [12]"}
{"id": "article-148244_5", "title": "Nirmatrelvir-Ritonavir -- Indications", "content": "According to the Centers for Disease Control and Prevention (CDC) report, less\u00a0than 1% of patients treated with nirmatrelvir-ritonavir required hospitalization or emergency department care.\u00a0\u00a0The patients who required hospitalization had advanced age(>60 years). [13] [14]", "contents": "Nirmatrelvir-Ritonavir -- Indications. According to the Centers for Disease Control and Prevention (CDC) report, less\u00a0than 1% of patients treated with nirmatrelvir-ritonavir required hospitalization or emergency department care.\u00a0\u00a0The patients who required hospitalization had advanced age(>60 years). [13] [14]"}
{"id": "article-148244_6", "title": "Nirmatrelvir-Ritonavir -- Mechanism of Action", "content": "Nirmatrelvir/ritonavir is a combination of two medications with distinct mechanisms of action. Nirmatrelvir, the first component, is a peptidomimetic inhibitor of Mpro, the SARS-CoV-2 main protease. Inhibiting Mpro prevents the virus from processing the polyprotein precursors it requires for viral replication.", "contents": "Nirmatrelvir-Ritonavir -- Mechanism of Action. Nirmatrelvir/ritonavir is a combination of two medications with distinct mechanisms of action. Nirmatrelvir, the first component, is a peptidomimetic inhibitor of Mpro, the SARS-CoV-2 main protease. Inhibiting Mpro prevents the virus from processing the polyprotein precursors it requires for viral replication."}
{"id": "article-148244_7", "title": "Nirmatrelvir-Ritonavir -- Mechanism of Action", "content": "Ritonavir, the second component, is a human immunodeficiency virus-1 (HIV-1) protease inhibitor with CYP3A-inhibiting effects. The latter effect allows it to be\u00a0used as a pharmacokinetic boosting agent to decrease the CYP3A-mediated metabolism of nirmatrelvir. Coadministration of nirmatrelvir with ritonavir is needed to increase the plasma concentration of nirmatrelvir enough to achieve the targeted therapeutic range. [15] Nirmatrelvir/ritonavir is effective against major variants of\u00a0SARS-CoV-2,\u00a0including omicron\u00a0variants. [16] The proposed\u00a0mechanism of resistance\u00a0is\u00a0the possibility of potential escape mutations. [17]", "contents": "Nirmatrelvir-Ritonavir -- Mechanism of Action. Ritonavir, the second component, is a human immunodeficiency virus-1 (HIV-1) protease inhibitor with CYP3A-inhibiting effects. The latter effect allows it to be\u00a0used as a pharmacokinetic boosting agent to decrease the CYP3A-mediated metabolism of nirmatrelvir. Coadministration of nirmatrelvir with ritonavir is needed to increase the plasma concentration of nirmatrelvir enough to achieve the targeted therapeutic range. [15] Nirmatrelvir/ritonavir is effective against major variants of\u00a0SARS-CoV-2,\u00a0including omicron\u00a0variants. [16] The proposed\u00a0mechanism of resistance\u00a0is\u00a0the possibility of potential escape mutations. [17]"}
{"id": "article-148244_8", "title": "Nirmatrelvir-Ritonavir -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: The time to maximum plasma concentration (Tmax) for nirmatrelvir(coadministered with\u00a0ritonavir) is approximately 3 hours. Administering\u00a0high-fat meals with nirmatrelvir/ritonavir increases the rate and extent of absorption.", "contents": "Nirmatrelvir-Ritonavir -- Mechanism of Action -- Pharmacokinetics. Absorption: The time to maximum plasma concentration (Tmax) for nirmatrelvir(coadministered with\u00a0ritonavir) is approximately 3 hours. Administering\u00a0high-fat meals with nirmatrelvir/ritonavir increases the rate and extent of absorption."}
{"id": "article-148244_9", "title": "Nirmatrelvir-Ritonavir -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: Plasma protein binding (PPB) for nirmatrelvir is 69% (coadministered with\u00a0ritonavir), PPB of ritonavir 98-99%. The mean volume of Distribution for nirmatrelvir is 104.7 L (coadministered with\u00a0ritonavir).", "contents": "Nirmatrelvir-Ritonavir -- Mechanism of Action -- Pharmacokinetics. Distribution: Plasma protein binding (PPB) for nirmatrelvir is 69% (coadministered with\u00a0ritonavir), PPB of ritonavir 98-99%. The mean volume of Distribution for nirmatrelvir is 104.7 L (coadministered with\u00a0ritonavir)."}
{"id": "article-148244_10", "title": "Nirmatrelvir-Ritonavir -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Nirmatrelvir is a human cytochrome CYP3A4 substrate, but when\u00a0administered with ritonavir, the metabolic clearance is minimal.\u00a0Ritonavir inhibits the metabolism of nirmatrelvir,\u00a0leading to\u00a0increased plasma concentrations of nirmatrelvir. Ritonavir is also metabolized by CYP2D6(minor). Excretion: The primary route of elimination for nirmatrelvir is renal, whereas ritonavir is eliminated primarily by hepatic metabolism in feces. [18]", "contents": "Nirmatrelvir-Ritonavir -- Mechanism of Action -- Pharmacokinetics. Metabolism: Nirmatrelvir is a human cytochrome CYP3A4 substrate, but when\u00a0administered with ritonavir, the metabolic clearance is minimal.\u00a0Ritonavir inhibits the metabolism of nirmatrelvir,\u00a0leading to\u00a0increased plasma concentrations of nirmatrelvir. Ritonavir is also metabolized by CYP2D6(minor). Excretion: The primary route of elimination for nirmatrelvir is renal, whereas ritonavir is eliminated primarily by hepatic metabolism in feces. [18]"}
{"id": "article-148244_11", "title": "Nirmatrelvir-Ritonavir -- Administration", "content": "The standard regimen is nirmatrelvir 300 mg (two 150 mg tablets) and ritonavir 100 mg (one 100 mg tablet), which are orally co-administered twice daily for five days and started within five days of symptom onset. Nirmatrelvir and ritonavir are co-packaged in convenience packs of 300 mg/100 mg or 150 mg/100 mg (for patients with moderate renal impairment). [3]", "contents": "Nirmatrelvir-Ritonavir -- Administration. The standard regimen is nirmatrelvir 300 mg (two 150 mg tablets) and ritonavir 100 mg (one 100 mg tablet), which are orally co-administered twice daily for five days and started within five days of symptom onset. Nirmatrelvir and ritonavir are co-packaged in convenience packs of 300 mg/100 mg or 150 mg/100 mg (for patients with moderate renal impairment). [3]"}
{"id": "article-148244_12", "title": "Nirmatrelvir-Ritonavir -- Administration", "content": "The medication should be taken at the same time each day. If a dose is missed within eight hours of the time it is typically assumed, it should be taken as soon as possible. However, the missed dose should be skipped if more than eight hours have elapsed. The FDA does not authorize nirmatrelvir/ritonavir\u00a0for\u00a0treatment\u00a0for longer than five days. Additionally, use is not approved for pre-exposure or post-exposure prophylaxis to prevent COVID-19.", "contents": "Nirmatrelvir-Ritonavir -- Administration. The medication should be taken at the same time each day. If a dose is missed within eight hours of the time it is typically assumed, it should be taken as soon as possible. However, the missed dose should be skipped if more than eight hours have elapsed. The FDA does not authorize nirmatrelvir/ritonavir\u00a0for\u00a0treatment\u00a0for longer than five days. Additionally, use is not approved for pre-exposure or post-exposure prophylaxis to prevent COVID-19."}
{"id": "article-148244_13", "title": "Nirmatrelvir-Ritonavir -- Administration -- Renal Impairment", "content": "Dose adjustment is not needed for mild renal impairment (eGFR >60 mL/min to <90 mL/min). Dose adjustment is needed for moderate renal impairment (eGFR >30 to <60 mL/min). Nirmatrelvir 150 mg (one 150 mg tablet) and ritonavir 100 mg (one 100 mg tablet) are orally co-administered twice daily for five days within five days of symptom onset. Nirmatrelvir/ritonavir is not recommended in those with severe renal impairment (eGFR <30 mL/min). [19] Use the CKD-EPI formula to calculate eGFR. [20] [21]", "contents": "Nirmatrelvir-Ritonavir -- Administration -- Renal Impairment. Dose adjustment is not needed for mild renal impairment (eGFR >60 mL/min to <90 mL/min). Dose adjustment is needed for moderate renal impairment (eGFR >30 to <60 mL/min). Nirmatrelvir 150 mg (one 150 mg tablet) and ritonavir 100 mg (one 100 mg tablet) are orally co-administered twice daily for five days within five days of symptom onset. Nirmatrelvir/ritonavir is not recommended in those with severe renal impairment (eGFR <30 mL/min). [19] Use the CKD-EPI formula to calculate eGFR. [20] [21]"}
{"id": "article-148244_14", "title": "Nirmatrelvir-Ritonavir -- Administration -- Hepatic Impairment", "content": "Dose adjustment is not needed for mild hepatic impairment (Child-Pugh Class A). Dose adjustment is not needed for moderate hepatic impairment (Child-Pugh Class B). Nirmatrelvir/ritonavir is not recommended for those with severe hepatic impairment (Child-Pugh Class C). [3]", "contents": "Nirmatrelvir-Ritonavir -- Administration -- Hepatic Impairment. Dose adjustment is not needed for mild hepatic impairment (Child-Pugh Class A). Dose adjustment is not needed for moderate hepatic impairment (Child-Pugh Class B). Nirmatrelvir/ritonavir is not recommended for those with severe hepatic impairment (Child-Pugh Class C). [3]"}
{"id": "article-148244_15", "title": "Nirmatrelvir-Ritonavir -- Administration", "content": "Pregnancy Considerations: Limited human data is available regarding drug-related risks of congenital disabilities, miscarriage, or other adverse maternal or fetal outcomes using nirmatrelvir in pregnant women. Human data on the use of ritonavir in pregnant women have not shown an increase in the risk of congenital disabilities.", "contents": "Nirmatrelvir-Ritonavir -- Administration. Pregnancy Considerations: Limited human data is available regarding drug-related risks of congenital disabilities, miscarriage, or other adverse maternal or fetal outcomes using nirmatrelvir in pregnant women. Human data on the use of ritonavir in pregnant women have not shown an increase in the risk of congenital disabilities."}
{"id": "article-148244_16", "title": "Nirmatrelvir-Ritonavir -- Administration", "content": "Animal studies of nirmatrelvir/ritonavir suggest that it can be safely used in pregnant women. Because pregnancy is a risk factor for developing severe COVID-19, nirmatrelvir/ritonavir should be offered to eligible pregnant women based on risk-benefit assessments. [22]", "contents": "Nirmatrelvir-Ritonavir -- Administration. Animal studies of nirmatrelvir/ritonavir suggest that it can be safely used in pregnant women. Because pregnancy is a risk factor for developing severe COVID-19, nirmatrelvir/ritonavir should be offered to eligible pregnant women based on risk-benefit assessments. [22]"}
{"id": "article-148244_17", "title": "Nirmatrelvir-Ritonavir -- Administration", "content": "Breastfeeding Considerations: Limited human data is available regarding the presence of nirmatrelvir in breast milk or its effects on breastfeeding infants. Human data demonstrate\u00a0that ritonavir is present at\u00a0low levels in breast milk and breastfed infants' blood.", "contents": "Nirmatrelvir-Ritonavir -- Administration. Breastfeeding Considerations: Limited human data is available regarding the presence of nirmatrelvir in breast milk or its effects on breastfeeding infants. Human data demonstrate\u00a0that ritonavir is present at\u00a0low levels in breast milk and breastfed infants' blood."}
{"id": "article-148244_18", "title": "Nirmatrelvir-Ritonavir -- Administration", "content": "Though ritonavir use during pregnancy is unlikely to have significant clinical implications, breastfeeding infants should still be monitored for the development of adverse effects.  Additionally, nirmatrelvir has\u00a0poor\u00a0oral bioavailability, and the\u00a0concentration\u00a0of ritonavir in milk is small; consequently, the combination of nirmatrelvir/ritonavir is unlikely to cause adverse drug reactions\u00a0in nursing\u00a0infants. [23]", "contents": "Nirmatrelvir-Ritonavir -- Administration. Though ritonavir use during pregnancy is unlikely to have significant clinical implications, breastfeeding infants should still be monitored for the development of adverse effects.  Additionally, nirmatrelvir has\u00a0poor\u00a0oral bioavailability, and the\u00a0concentration\u00a0of ritonavir in milk is small; consequently, the combination of nirmatrelvir/ritonavir is unlikely to cause adverse drug reactions\u00a0in nursing\u00a0infants. [23]"}
{"id": "article-148244_19", "title": "Nirmatrelvir-Ritonavir -- Adverse Effects", "content": "As nirmatrelvir/ritonavir is an investigational drug, there is limited clinical data about its potential adverse effects. However, data from the EPIC-HR trial suggests that it is generally well-tolerated by patients with COVID-19. The most common adverse effects include dysgeusia, diarrhea, hypertension, and myalgia. [3]", "contents": "Nirmatrelvir-Ritonavir -- Adverse Effects. As nirmatrelvir/ritonavir is an investigational drug, there is limited clinical data about its potential adverse effects. However, data from the EPIC-HR trial suggests that it is generally well-tolerated by patients with COVID-19. The most common adverse effects include dysgeusia, diarrhea, hypertension, and myalgia. [3]"}
{"id": "article-148244_20", "title": "Nirmatrelvir-Ritonavir -- Adverse Effects", "content": "In addition, hypersensitivity reactions, which may manifest\u00a0as\u00a0urticaria, angioedema, pruritus, and dyspnea, have been reported. Cases of anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have also been reported with ritonavir use. Hyperlipidemia, hypertriglyceridemia,\u00a0 and other metabolic adverse effects have also been noted with ritonavir. [24]", "contents": "Nirmatrelvir-Ritonavir -- Adverse Effects. In addition, hypersensitivity reactions, which may manifest\u00a0as\u00a0urticaria, angioedema, pruritus, and dyspnea, have been reported. Cases of anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have also been reported with ritonavir use. Hyperlipidemia, hypertriglyceridemia,\u00a0 and other metabolic adverse effects have also been noted with ritonavir. [24]"}
{"id": "article-148244_21", "title": "Nirmatrelvir-Ritonavir -- Adverse Effects", "content": "Hepatic transaminase elevations have been reported, but transaminase elevations have also been attributed to COVID-19(A confounding factor). The risk of hepatotoxicity is low, and the Likelihood score is E:(unlikely cause of clinically apparent liver injury). [25]", "contents": "Nirmatrelvir-Ritonavir -- Adverse Effects. Hepatic transaminase elevations have been reported, but transaminase elevations have also been attributed to COVID-19(A confounding factor). The risk of hepatotoxicity is low, and the Likelihood score is E:(unlikely cause of clinically apparent liver injury). [25]"}
{"id": "article-148244_22", "title": "Nirmatrelvir-Ritonavir -- Adverse Effects", "content": "Nirmatrelvir/ritonavir has significant drug-drug interactions due to the ritonavir component. As a potent CYP3A inhibitor, ritonavir can increase plasma concentrations of concomitant medications, increasing the risks of developing severe and life-threatening drug-related adverse effects. Due to these drug-drug interactions, many CYP3A-metabolized drugs are contraindicated in patients taking nirmatrelvir/ritonavir. [24]", "contents": "Nirmatrelvir-Ritonavir -- Adverse Effects. Nirmatrelvir/ritonavir has significant drug-drug interactions due to the ritonavir component. As a potent CYP3A inhibitor, ritonavir can increase plasma concentrations of concomitant medications, increasing the risks of developing severe and life-threatening drug-related adverse effects. Due to these drug-drug interactions, many CYP3A-metabolized drugs are contraindicated in patients taking nirmatrelvir/ritonavir. [24]"}
{"id": "article-148244_23", "title": "Nirmatrelvir-Ritonavir -- Adverse Effects", "content": "In patients with undiagnosed or uncontrolled HIV-1 infection, there is a theoretical risk that the use of nirmatrelvir/ritonavir will facilitate the development of antiviral cross-resistance against HIV-1 protease inhibitors due to the ritonavir component, which is an HIV-1 protease inhibitor; hence nirmatrelvir/ritonavir use is cautioned in patients with undiagnosed or uncontrolled HIV-1 infection. [24]", "contents": "Nirmatrelvir-Ritonavir -- Adverse Effects. In patients with undiagnosed or uncontrolled HIV-1 infection, there is a theoretical risk that the use of nirmatrelvir/ritonavir will facilitate the development of antiviral cross-resistance against HIV-1 protease inhibitors due to the ritonavir component, which is an HIV-1 protease inhibitor; hence nirmatrelvir/ritonavir use is cautioned in patients with undiagnosed or uncontrolled HIV-1 infection. [24]"}
{"id": "article-148244_24", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Nirmatrelvir/ritonavir is contraindicated if the patient has a history of clinically significant hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) to nirmatrelvir or ritonavir, other drugs in the same class, or drug components. [3]", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Nirmatrelvir/ritonavir is contraindicated if the patient has a history of clinically significant hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) to nirmatrelvir or ritonavir, other drugs in the same class, or drug components. [3]"}
{"id": "article-148244_25", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Moreover, nirmatrelvir/ritonavir is contraindicated with the concomitant use of medications that depend on CYP3A for clearance and whose elevated plasma concentrations are associated with serious and life-threatening adverse reactions which are due to the CYP3A-inhibiting effects of ritonavir, which can increase plasma concentrations of those medications to dangerous levels. [26] [27] Below is a partial list of those contraindicated medications and their potential adverse effects according to the FDA\u00a0prescriber fact sheet.", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Moreover, nirmatrelvir/ritonavir is contraindicated with the concomitant use of medications that depend on CYP3A for clearance and whose elevated plasma concentrations are associated with serious and life-threatening adverse reactions which are due to the CYP3A-inhibiting effects of ritonavir, which can increase plasma concentrations of those medications to dangerous levels. [26] [27] Below is a partial list of those contraindicated medications and their potential adverse effects according to the FDA\u00a0prescriber fact sheet."}
{"id": "article-148244_26", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Alpha-1-adrenoreceptor antagonists (alfuzosin): hypotension", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Alpha-1-adrenoreceptor antagonists (alfuzosin): hypotension"}
{"id": "article-148244_27", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Analgesics (pethidine): respiratory depression, hematologic abnormalities", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Analgesics (pethidine): respiratory depression, hematologic abnormalities"}
{"id": "article-148244_28", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Antianginals (ranolazine): serious and life-threatening reactions", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Antianginals (ranolazine): serious and life-threatening reactions"}
{"id": "article-148244_29", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Antiarrhythmics (amiodarone, dronedarone, flecainide, propafenone, quinidine): cardiac arrhythmias", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Antiarrhythmics (amiodarone, dronedarone, flecainide, propafenone, quinidine): cardiac arrhythmias"}
{"id": "article-148244_30", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Anticancer drugs (encorafenib, ivosidenib): QT interval prolongation", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Anticancer drugs (encorafenib, ivosidenib): QT interval prolongation"}
{"id": "article-148244_31", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Anti-gout drugs (colchicine): severe and life-threatening reactions in renal or hepatic impairment", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Anti-gout drugs (colchicine): severe and life-threatening reactions in renal or hepatic impairment"}
{"id": "article-148244_32", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Antipsychotics (lurasidone, pimozide, clozapine): cardiac arrhythmias", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Antipsychotics (lurasidone, pimozide, clozapine): cardiac arrhythmias"}
{"id": "article-148244_33", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Benign prostatic hyperplasia agents (silodosin): postural hypotension", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Benign prostatic hyperplasia agents (silodosin): postural hypotension"}
{"id": "article-148244_34", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Cardiovascular agents (eplerenone): hyperkalemia", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Cardiovascular agents (eplerenone): hyperkalemia"}
{"id": "article-148244_35", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Cardiovascular agents (ivabradine): bradycardia, conduction disturbances", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Cardiovascular agents (ivabradine): bradycardia, conduction disturbances"}
{"id": "article-148244_36", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Ergot derivatives (dihydroergotamine, ergotamine, methylergonovine): acute ergot toxicity", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Ergot derivatives (dihydroergotamine, ergotamine, methylergonovine): acute ergot toxicity"}
{"id": "article-148244_37", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "HMG-CoA reductase inhibitors (lovastatin, simvastatin): myopathy (including rhabdomyolysis)", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. HMG-CoA reductase inhibitors (lovastatin, simvastatin): myopathy (including rhabdomyolysis)"}
{"id": "article-148244_38", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Immunosuppressants (voclosporin): acute and chronic nephrotoxicity", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Immunosuppressants (voclosporin): acute and chronic nephrotoxicity"}
{"id": "article-148244_39", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Microsomal triglyceride transfer protein inhibitors (lomitapide): hepatotoxicity, gastrointestinal adverse effects(Possible increase\u00a0of AUC 27 fold)", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Microsomal triglyceride transfer protein inhibitors (lomitapide): hepatotoxicity, gastrointestinal adverse effects(Possible increase\u00a0of AUC 27 fold)"}
{"id": "article-148244_40", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Migraine medications (eletriptan, ubrogepant): cardiovascular and cerebrovascular adverse events", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Migraine medications (eletriptan, ubrogepant): cardiovascular and cerebrovascular adverse events"}
{"id": "article-148244_41", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Mineralocorticoid receptor antagonists (finerenone): hyperkalemia, hypotension, hyponatremia", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Mineralocorticoid receptor antagonists (finerenone): hyperkalemia, hypotension, hyponatremia"}
{"id": "article-148244_42", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "PDE5 inhibitors (sildenafil): visual abnormalities, hypotension, priapism, syncope", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. PDE5 inhibitors (sildenafil): visual abnormalities, hypotension, priapism, syncope"}
{"id": "article-148244_43", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Opioid antagonists (naloxegol): opioid withdrawal symptoms", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Opioid antagonists (naloxegol): opioid withdrawal symptoms"}
{"id": "article-148244_44", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Sedatives/hypnotics (triazolam, oral midazolam): respiratory depression, extreme sedation", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Sedatives/hypnotics (triazolam, oral midazolam): respiratory depression, extreme sedation"}
{"id": "article-148244_45", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Serotonin receptor 1A agonists/2A antagonists (flibanserin): hypotension, syncope, CNS depression", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Serotonin receptor 1A agonists/2A antagonists (flibanserin): hypotension, syncope, CNS depression"}
{"id": "article-148244_46", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Vasopressin receptor antagonists (tolvaptan): dehydration, hypovolemia, hyperkalemia", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Vasopressin receptor antagonists (tolvaptan): dehydration, hypovolemia, hyperkalemia"}
{"id": "article-148244_47", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "Furthermore, nirmatrelvir/ritonavir is contraindicated with the concomitant use of medications that are CYP3A inducers, which can decrease nirmatrelvir plasma concentrations to levels that result in loss of virologic response and development of antiviral resistance. This is due to nirmatrelvir/ritonavir being a CYP3A substrate whose plasma concentration is decreased by CYP3A inducers.", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. Furthermore, nirmatrelvir/ritonavir is contraindicated with the concomitant use of medications that are CYP3A inducers, which can decrease nirmatrelvir plasma concentrations to levels that result in loss of virologic response and development of antiviral resistance. This is due to nirmatrelvir/ritonavir being a CYP3A substrate whose plasma concentration is decreased by CYP3A inducers."}
{"id": "article-148244_48", "title": "Nirmatrelvir-Ritonavir -- Contraindications", "content": "The following\u00a0is a partial list of those contraindicated medications whose coadministration with nirmatrelvir/ritonavir can result in loss of virologic response and antiviral resistance. Below is a partial list of those contraindicated medications whose coadministration with nirmatrelvir/ritonavir can result in loss of virologic response and antiviral resistance. [26] [27] Anticancer drugs (apalutamide) Anticonvulsants (carbamazepine, phenobarbital, primidone, phenytoin) Antimycobacterial (rifampin) Cystic fibrosis drugs (lumacaftor/ivacaftor) Herbal products (St. John's Wort)", "contents": "Nirmatrelvir-Ritonavir -- Contraindications. The following\u00a0is a partial list of those contraindicated medications whose coadministration with nirmatrelvir/ritonavir can result in loss of virologic response and antiviral resistance. Below is a partial list of those contraindicated medications whose coadministration with nirmatrelvir/ritonavir can result in loss of virologic response and antiviral resistance. [26] [27] Anticancer drugs (apalutamide) Anticonvulsants (carbamazepine, phenobarbital, primidone, phenytoin) Antimycobacterial (rifampin) Cystic fibrosis drugs (lumacaftor/ivacaftor) Herbal products (St. John's Wort)"}
{"id": "article-148244_49", "title": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions", "content": "Ritonavir decreases the conversion to clopidogrel's active metabolite, leading to inadequate inhibition of platelet aggregation. Thus, it is recommended to avoid nirmatrelvir/ritonavir in patients at very high risk of thrombosis (e.g., early period post coronary stenting) unless clopidogrel can be switched to the noninteracting drug. [28] [29]", "contents": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions. Ritonavir decreases the conversion to clopidogrel's active metabolite, leading to inadequate inhibition of platelet aggregation. Thus, it is recommended to avoid nirmatrelvir/ritonavir in patients at very high risk of thrombosis (e.g., early period post coronary stenting) unless clopidogrel can be switched to the noninteracting drug. [28] [29]"}
{"id": "article-148244_50", "title": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions", "content": "Ritonavir has been shown to increase rivaroxaban AUC significantly and can potentially increase the risk of bleeding; thus, concurrent administration with nirmatrelvir/ritonavir is not advised. The management of this drug interaction would require pausing rivaroxaban and\u00a0switching to\u00a0alternative agents for the anticoagulation (such as edoxaban or LMWH). [28] [29]", "contents": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions. Ritonavir has been shown to increase rivaroxaban AUC significantly and can potentially increase the risk of bleeding; thus, concurrent administration with nirmatrelvir/ritonavir is not advised. The management of this drug interaction would require pausing rivaroxaban and\u00a0switching to\u00a0alternative agents for the anticoagulation (such as edoxaban or LMWH). [28] [29]"}
{"id": "article-148244_51", "title": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions", "content": "In patients receiving a ritonavir-boosted regimen with a calcineurin inhibitor(tacrolimus/cyclosporine), a significant increase in tacrolimus and cyclosporine exposure has been observed, which can lead to significant toxicity. Based on the clinical data, holding tacrolimus for eight days (i.e., five days during nirmatrelvir/ritonavir treatment and three days post-treatment) is recommended. [30]", "contents": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions. In patients receiving a ritonavir-boosted regimen with a calcineurin inhibitor(tacrolimus/cyclosporine), a significant increase in tacrolimus and cyclosporine exposure has been observed, which can lead to significant toxicity. Based on the clinical data, holding tacrolimus for eight days (i.e., five days during nirmatrelvir/ritonavir treatment and three days post-treatment) is recommended. [30]"}
{"id": "article-148244_52", "title": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions", "content": "According to the French Society of Pharmacology and Therapeutics, coadministration of fentanyl with nirmatrelvir/ritonavir may increase the exposure of fentanyl with the risk of severe respiratory\u00a0depression. [28] [29]", "contents": "Nirmatrelvir-Ritonavir -- Contraindications -- Management of Potential Drug-drug Interactions. According to the French Society of Pharmacology and Therapeutics, coadministration of fentanyl with nirmatrelvir/ritonavir may increase the exposure of fentanyl with the risk of severe respiratory\u00a0depression. [28] [29]"}
{"id": "article-148244_53", "title": "Nirmatrelvir-Ritonavir -- Monitoring", "content": "Patients taking nirmatrelvir/ritonavir\u00a0requires close monitoring for adverse reactions, such as hypersensitivity and drug-drug interactions. [7] Moreover, clinicians may consider therapeutic concentration monitoring of coadministered medications that CYP3A metabolizes. Certain medications, such as warfarin, may require additional monitoring of factors such as the international normalized ratio (INR). [31] Furthermore, clinicians may consider checking renal and liver function in patients taking nirmatrelvir/ritonavir, especially those with pre-existing renal and hepatic impairment. TDM (Therapeutic drug monitoring) is required for narrow therapeutic drugs like cyclosporine and tacrolimus when coadministered with nirmatrelvir/ritonavir. [30] [32]", "contents": "Nirmatrelvir-Ritonavir -- Monitoring. Patients taking nirmatrelvir/ritonavir\u00a0requires close monitoring for adverse reactions, such as hypersensitivity and drug-drug interactions. [7] Moreover, clinicians may consider therapeutic concentration monitoring of coadministered medications that CYP3A metabolizes. Certain medications, such as warfarin, may require additional monitoring of factors such as the international normalized ratio (INR). [31] Furthermore, clinicians may consider checking renal and liver function in patients taking nirmatrelvir/ritonavir, especially those with pre-existing renal and hepatic impairment. TDM (Therapeutic drug monitoring) is required for narrow therapeutic drugs like cyclosporine and tacrolimus when coadministered with nirmatrelvir/ritonavir. [30] [32]"}
{"id": "article-148244_54", "title": "Nirmatrelvir-Ritonavir -- Monitoring", "content": "Clinicians and healthcare facilities must be aware of mandatory reporting requirements. Prescribers are mandated to use FDA Form 3500 to report all medication errors and serious adverse events related to nirmatrelvir/ritonavir to FDA MedWatch(https://www.fda.gov/medwatch/report.htm). The adverse event must be reported to Pfizer according to the package insert. In addition, clinicians and healthcare facilities must report therapeutics information and utilization data to the US Department of Health and Human Services.", "contents": "Nirmatrelvir-Ritonavir -- Monitoring. Clinicians and healthcare facilities must be aware of mandatory reporting requirements. Prescribers are mandated to use FDA Form 3500 to report all medication errors and serious adverse events related to nirmatrelvir/ritonavir to FDA MedWatch(https://www.fda.gov/medwatch/report.htm). The adverse event must be reported to Pfizer according to the package insert. In addition, clinicians and healthcare facilities must report therapeutics information and utilization data to the US Department of Health and Human Services."}
{"id": "article-148244_55", "title": "Nirmatrelvir-Ritonavir -- Monitoring", "content": "Clinicians should also monitor patients\u00a0who complete their regimen of nirmatrelvir/ritonavir for rebound and recurrence of COVID-19 symptoms. [33] At this time, the mechanism, incidence, and implications of this rebound effect are unknown.\u00a0According to the CDC and FDA, additional treatment with nirmatrelvir/ritonavir is not required when a rebound/recurrence is suspected. [34]", "contents": "Nirmatrelvir-Ritonavir -- Monitoring. Clinicians should also monitor patients\u00a0who complete their regimen of nirmatrelvir/ritonavir for rebound and recurrence of COVID-19 symptoms. [33] At this time, the mechanism, incidence, and implications of this rebound effect are unknown.\u00a0According to the CDC and FDA, additional treatment with nirmatrelvir/ritonavir is not required when a rebound/recurrence is suspected. [34]"}
{"id": "article-148244_56", "title": "Nirmatrelvir-Ritonavir -- Toxicity", "content": "Nirmatrelvir/ritonavir has significant drug-drug interactions due to the ritonavir component. As a potent CYP3A inhibitor, ritonavir can increase the plasma concentrations of concomitant medications whose metabolism depends on CYP3A, increasing the risks of serious and life-threatening toxicities. In addition, ritonavir use is associated with hepatotoxicity, with reports of hepatitis, jaundice, and elevated transaminases. Patients taking nirmatrelvir/ritonavir, with or without other medications, should be monitored for drug-related toxicities. [24]", "contents": "Nirmatrelvir-Ritonavir -- Toxicity. Nirmatrelvir/ritonavir has significant drug-drug interactions due to the ritonavir component. As a potent CYP3A inhibitor, ritonavir can increase the plasma concentrations of concomitant medications whose metabolism depends on CYP3A, increasing the risks of serious and life-threatening toxicities. In addition, ritonavir use is associated with hepatotoxicity, with reports of hepatitis, jaundice, and elevated transaminases. Patients taking nirmatrelvir/ritonavir, with or without other medications, should be monitored for drug-related toxicities. [24]"}
{"id": "article-148244_57", "title": "Nirmatrelvir-Ritonavir -- Toxicity", "content": "In the event of an overdose of nirmatrelvir/ritonavir, management entails general supportive measures, including close monitoring of vital signs and observation of clinical status. There is no antidote specifically for an overdose of nirmatrelvir/ritonavir. The poison center should be contacted in the case of an overdose with nirmatrelvir/ritonavir for recommendations by medical toxicologists. [35]", "contents": "Nirmatrelvir-Ritonavir -- Toxicity. In the event of an overdose of nirmatrelvir/ritonavir, management entails general supportive measures, including close monitoring of vital signs and observation of clinical status. There is no antidote specifically for an overdose of nirmatrelvir/ritonavir. The poison center should be contacted in the case of an overdose with nirmatrelvir/ritonavir for recommendations by medical toxicologists. [35]"}
{"id": "article-148244_58", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "As stated above, ritonavir is a potent CYP3A inhibitor with significant drug-drug interactions that can potentially cause life-threatening adverse events. [24] Therefore, the healthcare team must be extremely cautious when prescribing nirmatrelvir/ritonavir to patients taking other medications. An interprofessional team of clinicians, pharmacists, nurses, and other health professionals can minimize the risk of these drug-drug interactions and improve patient-centered care, health outcomes, and patient safety.", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. As stated above, ritonavir is a potent CYP3A inhibitor with significant drug-drug interactions that can potentially cause life-threatening adverse events. [24] Therefore, the healthcare team must be extremely cautious when prescribing nirmatrelvir/ritonavir to patients taking other medications. An interprofessional team of clinicians, pharmacists, nurses, and other health professionals can minimize the risk of these drug-drug interactions and improve patient-centered care, health outcomes, and patient safety."}
{"id": "article-148244_59", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "Clinicians\u00a0and pharmacists (authorized under the FDA EUA to prescribe nirmatrelvir/ritonavir\u00a0to eligible patients) should obtain a comprehensive history to determine whether patients are candidates for the medication. [36] Given the many known drug-drug interactions, the healthcare team should perform thorough medication reconciliation, including prescription and over-the-counter medications, herbal supplements, and recreational drugs. [37]", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. Clinicians\u00a0and pharmacists (authorized under the FDA EUA to prescribe nirmatrelvir/ritonavir\u00a0to eligible patients) should obtain a comprehensive history to determine whether patients are candidates for the medication. [36] Given the many known drug-drug interactions, the healthcare team should perform thorough medication reconciliation, including prescription and over-the-counter medications, herbal supplements, and recreational drugs. [37]"}
{"id": "article-148244_60", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "If potential drug-drug interactions exist, all healthcare team members should be informed to not only help prevent adverse events but also implement any corrective measures if necessary. In addition, dose adjustments of concomitant medications might be necessary for patients at risk of drug-drug interactions or those with moderate renal impairment. [19] Initial dosing and dose adjustments should be made under the guidance of a\u00a0clinician and pharmacist.", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. If potential drug-drug interactions exist, all healthcare team members should be informed to not only help prevent adverse events but also implement any corrective measures if necessary. In addition, dose adjustments of concomitant medications might be necessary for patients at risk of drug-drug interactions or those with moderate renal impairment. [19] Initial dosing and dose adjustments should be made under the guidance of a\u00a0clinician and pharmacist."}
{"id": "article-148244_61", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "Patients taking nirmatrelvir/ritonavir should be monitored by the interprofessional team. In addition, patients need to be provided with a fact sheet for patient education. Nurses are ideally situated to\u00a0observe\u00a0for adverse reactions, assess patient compliance with their regimen, and inform the healthcare team of their findings. However, as stated above, all healthcare team members are mandated to report serious medication errors and adverse events to FDA MedWatch and the drug's manufacturer.", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. Patients taking nirmatrelvir/ritonavir should be monitored by the interprofessional team. In addition, patients need to be provided with a fact sheet for patient education. Nurses are ideally situated to\u00a0observe\u00a0for adverse reactions, assess patient compliance with their regimen, and inform the healthcare team of their findings. However, as stated above, all healthcare team members are mandated to report serious medication errors and adverse events to FDA MedWatch and the drug's manufacturer."}
{"id": "article-148244_62", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "As nirmatrelvir/ritonavir is an investigational medicine, the healthcare team must be aware of the indications, contraindications, mechanism of action, adverse effects, toxicity, and monitoring when managing the care of patients with COVID-19. In addition to the duties mentioned above, all healthcare team members are responsible for educating and counseling patients. Given that nirmatrelvir/ritonavir is the only oral highly-effective antiviral against COVID-19 at this time, judicious use can help curb COVID-19-related morbidity and mortality while minimizing the risk of drug-related adverse events.", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. As nirmatrelvir/ritonavir is an investigational medicine, the healthcare team must be aware of the indications, contraindications, mechanism of action, adverse effects, toxicity, and monitoring when managing the care of patients with COVID-19. In addition to the duties mentioned above, all healthcare team members are responsible for educating and counseling patients. Given that nirmatrelvir/ritonavir is the only oral highly-effective antiviral against COVID-19 at this time, judicious use can help curb COVID-19-related morbidity and mortality while minimizing the risk of drug-related adverse events."}
{"id": "article-148244_63", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "The FDA announced that pharmacists could also prescribe nirmatrelvir/ritonavir; however, patients are required to bring health records(<1 year old), with reports of liver and kidney function along with a comprehensive(including OTC) list of all medications, so the pharmacist can screen for potentially serious drug interactions and check for prescribing eligibility. The FDA has recommended that the pharmacist refer the patient to a physician, advanced practice nurse, or physician assistant if the above criteria are not met.", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. The FDA announced that pharmacists could also prescribe nirmatrelvir/ritonavir; however, patients are required to bring health records(<1 year old), with reports of liver and kidney function along with a comprehensive(including OTC) list of all medications, so the pharmacist can screen for potentially serious drug interactions and check for prescribing eligibility. The FDA has recommended that the pharmacist refer the patient to a physician, advanced practice nurse, or physician assistant if the above criteria are not met."}
{"id": "article-148244_64", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "Consequently, the interprofessional approach with excellent communication between physicians, advanced practice nurses, physician assistants, pharmacists, and specialists are required to accomplish optimal outcomes for nirmatrelvir/ritonavir therapy in patients with COVID-19. This includes meticulous documentation of all interactions and interventions with the patient so that all team members have the same patient data from which to make decisions regarding care. [36] [Level 5]", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. Consequently, the interprofessional approach with excellent communication between physicians, advanced practice nurses, physician assistants, pharmacists, and specialists are required to accomplish optimal outcomes for nirmatrelvir/ritonavir therapy in patients with COVID-19. This includes meticulous documentation of all interactions and interventions with the patient so that all team members have the same patient data from which to make decisions regarding care. [36] [Level 5]"}
{"id": "article-148244_65", "title": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes", "content": "Finally, genetic\u00a0sequencing\u00a0of patients treated with\u00a0nirmatrelvir/ritonavir is crucial due to the potential for antiviral resistance\u00a0to SARS-CoV-2. [17] Antiviral stewardship is vital, and antivirals, including nirmatrelvir/ritonavir, should be used judiciously. [38]", "contents": "Nirmatrelvir-Ritonavir -- Enhancing Healthcare Team Outcomes. Finally, genetic\u00a0sequencing\u00a0of patients treated with\u00a0nirmatrelvir/ritonavir is crucial due to the potential for antiviral resistance\u00a0to SARS-CoV-2. [17] Antiviral stewardship is vital, and antivirals, including nirmatrelvir/ritonavir, should be used judiciously. [38]"}
{"id": "article-148244_66", "title": "Nirmatrelvir-Ritonavir -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Nirmatrelvir-Ritonavir -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}